Efficacy of NIV Masks in COPD
Efficacy of NIV Masks in COPD Patients With Chronic Respiratory Failure: A Randomized Controlled Cross Over Pilot
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Wellington, New Zealand, 6021
- Medical Research Institute New Zealand
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A doctor's diagnosis of COPD
- PtCO2 ≥45mmHg on transcutaneous monitor at baseline measure
- Oxygen saturation measured by pulse oximetry (SpO2) ≥85%
- Fits the study mask
- Can tolerate the therapy
Exclusion Criteria:
- FEV1/FVC ≥70%
- Body mass index >35
- Hypercapnia considered to be primarily due to Obesity Hypoventilation syndrome and/or Obstructive Sleep Apnea
- Any condition which makes NIV contra-indicated as per BTS guidelines based on clinical judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Investigation Mask
Bi Level CPAP Mask
|
Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
|
|
Active Comparator: Comparator Mask
Bi Level CPAP Mask
|
Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transcutaneous Carbon Dioxide
Time Frame: 60 minutes
|
mmHg
|
60 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygen Saturation
Time Frame: 60 minutes
|
Percentage
|
60 minutes
|
|
Minute Ventilation
Time Frame: 60 minutes
|
Litres
|
60 minutes
|
|
Heart Rate
Time Frame: 60 minutes
|
Beats per minute
|
60 minutes
|
|
Respiratory Rate
Time Frame: 60 minutes
|
Breaths per minute
|
60 minutes
|
|
Borg Dyspnoea Score
Time Frame: 60 Minutes
|
1-6 Ranking, with 1 being best and 6 being worst
|
60 Minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alex Semprini, Medical Research Institute of New Zealand
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CIA293
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.